Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Hepatopulmonary Syndrome

sorafenib has been researched along with Hepatopulmonary Syndrome in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Al-Naamani, N; Brown, R; Doyle, MF; Ellenberg, SS; Fallon, MB; Fox, A; Goldberg, D; Gupta, S; Kaplan, DE; Kawut, SM; Koch, D; Krowka, MJ; Levitsky, J; Lin, G; Mottram, C; Oh, JK; Sharkoski, T; Song, N; Vargas, H1
Swanson, KL1
Alpini, G; Fallon, MB; Hu, B; Venter, J; Wu, W; Yang, W; Zhang, J1
Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM1
Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS1

Trials

2 trial(s) available for sorafenib and Hepatopulmonary Syndrome

ArticleYear
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2019, Volume: 25, Issue:8

    Topics: Biomarkers; Double-Blind Method; Echocardiography; Female; Hepatopulmonary Syndrome; Humans; Male; Middle Aged; Neovascularization, Pathologic; Placebos; Proof of Concept Study; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Treatment Outcome

2019
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.
    Journal of vascular and interventional radiology : JVIR, 2012, Volume: 23, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatopulmonary Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Radiotherapy, Adjuvant; Sorafenib; Treatment Outcome

2012

Other Studies

3 other study(ies) available for sorafenib and Hepatopulmonary Syndrome

ArticleYear
Translational Research in Hepatopulmonary Syndrome: Lessons Learned Despite Negative Results.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2019, Volume: 25, Issue:8

    Topics: Double-Blind Method; Hepatopulmonary Syndrome; Humans; Liver Transplantation; Negative Results; Sorafenib; Translational Research, Biomedical

2019
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.
    American journal of physiology. Gastrointestinal and liver physiology, 2014, Jan-01, Volume: 306, Issue:1

    Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmonary Syndrome; Ligation; Lung; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2014
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.
    Clinical science (London, England : 1979), 2013, Volume: 124, Issue:7

    Topics: Animals; Benzenesulfonates; Common Bile Duct; Disease Models, Animal; Hemodynamics; Hepatopulmonary Syndrome; Ligation; Liver; Liver Cirrhosis, Biliary; Liver Diseases; Lung; Male; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2013